Search results (58)
« Back to News & OpinionNews and Opinion from the Pandemic Sciences Institute at the University of Oxford
Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing
1 June 2026
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.
Media spotlight: PSI experts on Bundibugyo Ebola vaccines and treatments
28 May 2026
Several UK and global outlets have covered Oxford’s response to the Bundibugyo Ebola virus outbreak currently affecting the DRC and Uganda.
Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC
22 May 2026
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
Improving early diagnosis of HIV and Hepatitis B and C with machine learning algorithms
12 May 2026
The BMC Infectious Diseases study is the first to investigate the integration of machine learning algorithms with primary care data to support testing for blood-borne diseases.
Oxford and Serum Institute of India sign IP licence agreement to advance NipahB vaccine candidate
16 March 2026
The agreement will enable the Serum Institute of India to support the development, manufacture and potential future supply of the vaccine candidate developed by PSI scientists.
PSI supports the 100 Days Mission Implementation Report’s call to reinvigorate pandemic preparedness research and development
28 January 2026
Several PSI activities and initiatives have been identified as contributing to the 100 Days Mission's goal to prepare as much as possible within the first 100 days of a pandemic.
Ambitious research aiming to develop multivalent vaccines to protect against multiple deadly filoviruses
8 January 2026
Working with international partners, scientists across PSI and OVG will design and develop multivalent vaccine candidates with funding from CEPI and Horizon Europe.
Driving the development of new tools to combat Nipah virus outbreaks
18 December 2025
- Ethics, social science & humanities
- Nipah virus
- Pathogen biology & new threats
- Research news
- Vaccines, treatments, diagnostics & trials
PSI’s Nipah Virus Research Day, held on Wednesday, 19 November 2025, showcased promising developments, spanning new insights into Nipah virus biology, clinical trials of vaccines, the development of policy responses, and progress in developing diagnostics and treatments, all of which are helping improve responses to outbreaks of this deadly virus.
International collaboration launches largest-ever therapeutics trial for patients hospitalised with dengue
10 December 2025
A landmark international research collaboration has launched the largest clinical trial ever conducted to test therapeutics for moderate-severe dengue, a mosquito-borne viral disease that continues to spread rapidly driven by climate change and globalisation.
World's first Phase II Nipah virus vaccine trial launch
9 December 2025
The trial will assess the safety and immune response of the ChAdOx1 NipahB vaccine, developed by PSI scientists, in a region where the virus causes recurrent outbreaks.
First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial
4 December 2025
The vaccine developed by PSI researchers aims to advance the fight against Lassa fever virus, a WHO priority pathogen posing a significant public health risk.
PSI-Dr Jenner’s House collaborative school’s programme wins educational award
27 November 2025
The Frances Garnham Award for Education celebrates innovative approaches to educational or community engagement.
New research reveals optimal time intervals for COVID-19 vaccine boosters
1 September 2025
Two new papers from University of Oxford scientists have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
PSI-industry oral vaccine project aims to transform immunisation strategies
18 August 2025
The project led by Professor Dame Sarah Gilbert is one of the winners of the first VaxHub Sustainable Platform Funding Call.
Bubonic plague treatment proven highly effective and safe in global first
6 August 2025
Researchers from the UK and Madagascar, in collaboration with Madagascar’s health services and national plague programme, have conducted the world’s first rigorous clinical trial of treatments for bubonic plague.
HRH The Duke of Gloucester visits University of Oxford’s cutting-edge vaccine facilities
25 July 2025
The visit to the Clinical BioManufacturing Facility and the laboratories of the Oxford Vaccine Group and Pandemic Sciences Institute showcased Oxford’s global leadership in medical science and innovation.
Oxford vaccine against deadly Nipah virus granted European Medicines Agency PRIME designation
9 June 2025
The designation recognises the vaccine’s potential to address the unmet medical need arising from the devastating Nipah virus disease, which can be fatal in up to 85% of cases.
New research published on maximising mpox vaccine availability
5 June 2025
Scientists have studied the immune response of a dose-sparing regimen to expand vaccine supply and protect more people from mpox.
Up to £16.5 million awarded to global consortium to overcome obstacles in infectious disease research
8 April 2025
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to £16.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
RECOVERY trial team win NIHR Impact Prize
21 March 2025
Co-led by PSI Director Professor Sir Peter Horby, the RECOVERY trial was defined "one of the most well-known studies supported by the NIHR with clear national and global impact”.